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ABSTRACT
Drug resistance is a major challenge for the treatment
of many diseases and a significant concern through-
out the drug development process. The ability to
understand and predict the effects of mutations on
protein–ligand affinities and their roles in the emer-
gence of resistance would significantly aid treat-
ment and drug design strategies. In order to study
and understand the impacts of missense mutations
on the interaction of ligands with the proteome, we
have developed Platinum (http://structure.bioc.cam.
ac.uk/platinum). This manually curated, literature-
derived database, comprising over 1000 mutations,
associates for the first time experimental information
on changes in affinity with three-dimensional struc-
tures of protein–ligand complexes. To minimize dif-
ferences arising from experimental techniques and to
directly compare binding affinities, Platinum consid-
ers only changes measured by the same group and
with the same amino-acid sequence used for struc-
ture determination, providing a direct link between
protein structure, how a ligand binds and how mu-
tations alter the affinity of the ligand of the protein.
We believe Platinum will be an invaluable resource
for understanding the effects of mutations that give
rise to drug resistance, a major problem emerging in
pandemics including those caused by the influenza
virus, in infectious diseases such as tuberculosis, in
cancer and in many other life-threatening illnesses.
INTRODUCTION
Mutations can result in a range of changes to protein func-
tion by altering its stability and affinity for binding part-
ners including other proteins and peptides, nucleic acids and
small molecules. The strong selective pressure imposed by
small molecule drugs on many quickly evolving systems,
including viruses, bacteria and human cancer, can lead to
the rapid development of resistance (1–4). While rapid and
cheaper DNA sequencing has allowed these mutations to
be quickly identified in members of large populations (5,6),
the significance and characterization of any novel polymor-
phisms currently requires time-consuming and costly exper-
iments.
Ligand-binding affinity data for proteins have been an es-
sential source of information for understanding the effects
of polymorphisms in disease (7), in addition to identifying
those that result in the development of resistance, an in-
creasingly significant problem (8,9). Efforts to link missense
mutations to the development of resistance in specific dis-
eases, for example in cancer, tuberculosis and HIV (10–12),
have highlighted the importance of these mutations. How-
ever, the understanding of the effects of mutations on ligand
binding will help expand our knowledge of mechanisms of
action, allowing extrapolations to novel mutations and sys-
tems. Awareness of these changes is also an essential step
toward more effective, personalized and targeted treatment
strategies. For example, the resistance profile of emerging in-
fluenza strains has been of significant interest to ensure that
appropriate antiviral therapeutics can be rapidly adminis-
tered in the event of an outbreak (13).
Databases that have linked non-synonymous single nu-
cleotide polymorphisms (nsSNPs) with structural informa-
tion and experimentally measured changes in thermody-
namic data (14–16) have enabled the development of com-
putational approaches to evaluate missense mutations (17–
19) for their effects on protein stability and binding to pro-
tein and nucleic acid partners, expanding our understand-
ing of their roles in disease. Despite its relevance and po-
tential to support studies on emerging phenomena such as
drug resistance, no such information is readily available to
interrogate the effects of mutations on ligand-binding affin-
ity.
A compilation of small molecule structural and affin-
ity data for wild-type and mutant proteins would therefore
be a valuable resource for developing methods to elucidate
mechanisms behind ligand binding and to predict the ef-
*To whom correspondence should be addressed. Tel: +44 1223766033; Fax: +44 1223766002; Email: dascher@svi.edu.au
Correspondence may also be addressed to Douglas E.V. Pires. Tel: +44 1223766033; Fax: +44 1223766002; Email: dpires@dcc.ufmg.br
C© The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
D388 Nucleic Acids Research, 2015, Vol. 43, Database issue
fects of mutations. In order to fill this gap, we have designed
and implemented a freely accessible database, called Plat-
inum, which compiles and associates small molecule affin-
ity data with structural information, experimental meth-
ods and conditions, and ligand properties. Furthermore,
we have provided a web interface to facilitate searching the
database, sorting, visualizing and downloading the results
(http://structure.bioc.cam.ac.uk/platinum).
MATERIALS AND METHODS
Data acquisition and curation
The scientific literature available in PubMed was mined in
order to select papers containing structural information of
protein–ligand complexes and affinity data for complexes of
both wild-type and mutant proteins.
An initial pool of papers was compiled formanual inspec-
tion by selecting those with mutation information associ-
ated with deposited protein–ligand complexes in the RCSB
Protein Data Bank (20). In order to do so, paper titles and
abstracts were filtered using regular expression matching in
order to identify candidates for manual curation. The set of
terms used on the regular expressions included root words
of ‘mutation’, ‘resistance’ and mutation codes in the format
<WT-Res><Res-Num><MT-Res>, whereWT-Res is the
one-letter code for the wild-type, Res-Num is the residue
number and MT-Res is the one-letter code for the mutant
residue.
This procedure identified over 1000 papers, which were
manually evaluated against filtering criteria that include re-
quiring affinity data for the construct for which the three-
dimensional structure had been determined.
To minimize differences arising from experimental tech-
niques and to be able to compare directly binding affinities
(21), we considered only affinity changes measured by the
same group, using the same technique and conditions, and
with the same amino-acid sequence used to determine the
three-dimensional structure, providing a direct link between
protein structure, how a ligand binds and how mutations
alter the affinity of the ligand for the protein. EC50/IC50
measurements in the absence of theMichaelis constant were
not considered due to their inherent dependency on experi-
mental conditions, and incompatibility with binding affini-
ties. Only data from techniques that directlymeasure the lig-
and affinity to a protein were entered into Platinum, since
indirect methods such as cellular assays have many con-
founding factors and were therefore discarded.
Approximately 20% of the identified papers matched our
criteria and were manually curated to obtain data that
would reflect the effects of mutations on protein–ligand
affinity. Over 1000 different affinity data points were man-
ually collated from 182 papers indexed by PubMed. Ad-
ditional details regarding the experimental techniques and
conditions were also entered into Platinum. The PDB-
coordinate files for 250 different protein–ligand complexes
were downloaded from the RCSB Protein Data Bank, pre-
processed and used to supply additional information re-
garding the protein.
In order to account for additional consequences of the
mutations, the predicted effects of single pointmutations on
protein stability in the three-dimensional structure were cal-
culated using the integrated approach DUET (17), when a
wild-type PDB structure is available. The effects of the mu-
tations on the affinity of a protein–protein interface were
predicted by mCSM-PPI (18) when a single-point mutation
waswithin 5 A˚ of a biologically relevant interface, as defined
by the author-assigned assemblies.
Ligand properties such as molecular weight, logP, num-
ber of hydrogen acceptors and donors were calculated us-
ing RDKit and complementary ligand information such
as Canonical Smiles and ligand type were obtained from
the PDBeChem (22). All entries were manually double-
checked, with additional filters used to confirm the cor-
rectness of all structural and affinity information. Figure 1
shows the workflow for data collection and curation used to
build Platinum.
Database architecture and web interface
The collected data were consolidated as a MySQL rela-
tional database (version 5.5.35). The information stored in
Platinum can be easily queried and downloaded via a user-
friendly web interface. Its front-end was implemented us-
ing the Bootstrap framework version 2.0, while the back-
end was built in Python via the Flask framework (version
0.10.1), running on a Linux server.
RESULTS: DATABASE FEATURES
Web interface
The web interface to the database displays the home page
of Platinum. From here users can access the entire database
through a ‘Browse’ function or query the database through
a ‘Search’ function (Figure 2). For each data point, dis-
played by default (Supplementary Figure S1 in Supple-
mentary Material) are the protein name, mutation details,
whether the mutation is within 5 A˚ of the ligand-binding
site, the ligand ID (as appears in the PDB), the type of affin-
ity measurement, the affinity for the ligand of the reference
and mutant proteins (nM), the PDB codes of the reference
and/or mutant protein in complex with the ligand and the
PubMed ID of the paper where the affinity data were pub-
lished.
Additional information regarding the mutation, protein,
ligand and affinity measurements can be toggled on and
off depending on requirements of the user. Detailed infor-
mation of thelocation of the mutation, including secondary
structure, hydrogen bonding and solvent accessibility of the
reference residue, can be displayed by toggling on residue
properties. The extra experimental information includes the
method, pH and temperature at which the affinities were
measured, as well as the predicted changes in the affinity.
The ‘protein toggle’ reveals information about the struc-
ture, including the organism, resolution and R-factors. The
‘ligand toggle’ will show several properties calculated using
RDKit or obtained from PDBeChem. To facilitate down-
stream analysis, hyperlinks to the RCSB PDB entries and
PubMed abstracts have been included.
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Figure 1. Architecture of data integration and curation of Platinum.
Figure 2. Platinums web interface search page. It allows users to query the
database by combining different searching criteria such as ligand type, or-
ganism from which the protein originates and functional classification as
well as mutation properties.
Querying the database and downloading the results
The database can be queried using the web interface (Fig-
ure 2). This provides the ability to search the database by
ligand and protein type, the kingdom of the organism from
which the protein originates, the effect of the mutation on
the affinity for the ligand, how the affinity was measured
and whether only high-resolution structures,KD’s or single-
point mutations should be displayed.
The web interface also provides several methods for ex-
porting data. Firstly, the entire platinum database can be
downloaded as a comma-delimited file. All the processed
and filtered PDB files linked in Platinum can also be down-
loaded as a separate file. Secondly, the results retrieved by a
query can be exported separately as a comma-delimited file.
Table 1. Overview of data represented in Platinum
Property Frequency
#Mutations 1008
#Single-point mutations 797
#Papers (by PMID) 182
#Unique Uniprots 142
#Unique ligands 207
#Unique protein-ligand
complexes
250
#Total unique PDB IDs 451
#Affinities given in KD 560
Data statistics
Currently Platinum contains more than 1000 unique data
points, with 72% of mutations leading to either a significant
increase (16%) or decrease (56%) in protein–ligand affin-
ity of over 2-fold (Figure 3A). Most mutations in Platinum
(75%) involve residues directly interacting with the ligand
in the three-dimensional structure. Approximately 80% of
the data points are from single-point mutations, which are
more amenable to computational predictions. The informa-
tion stored in the database represents a diverse range of pro-
teins, ligands and interactions, as summarized in Table 1.
The ligands in the database are quite varied, with molec-
ular weights ranging from 90 to 900 Da (Figure 3B) and
including fragments, inhibitors and therapeutics as well as
natural co-factors and substrates (other properties of lig-
ands in Platinum are also depicted in Supplementary Figure
S2 of Supplementary Material). The proteins present in the
database represent a wide range of biological activities (Fig-
ure 3C) highlighting the broad range of effects encompassed
within Platinum.While the proteins are from a diverse selec-
tion of organisms, themajority (60%) are from organisms in
the Bacterial Domain and Animalia Kingdom (Figure 3D),
with approximately 20%of the data fromHomo sapiens pro-
teins. This reflects the research emphasis within these areas.
DISCUSSION
The threat of resistance to current therapies is becoming of
increasing concern and is widely publicized, especially in re-
gard to the use of antibiotics (23) and emerging pandemics
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Figure 3. Platinum entries statistics. In (A), the histogram of the density distribution of the effect of mutations on protein–ligand affinity within Platinum
is shown as the fold change (ratio between affinities of reference and mutant). In (B), the histogram of the density distribution of molecular weights of
unique ligands in Platinum is shown. The proteins in Platinum are classified by their function, with the proportion of proteins in the most common classes
shown in (C). The proteins are also classified phylogenetically in groups and the proportion of data points per class is shown in (D).
including those caused by the influenza virus (4), in infec-
tious diseases such as tuberculosis (24), in cancer (3) and
many other life-threatening illnesses. A repository of mu-
tations and the protein structures within which they occur
should be a useful tool to aid the understanding of ligand
binding, the development of resistance or the target of a
drug or chemical tool. However, no attempt has been made
previously to catalog these results, and thus this useful in-
formation is currently difficult to access.
Previous resources such as PDBbind (25), AffinDB (26)
and BindingMOAD (27) provide only the affinity for crys-
tal complexes, while Platinum also maps the effects of mu-
tations on binding affinity. Platinum is also significantly dif-
ferent from BindingDB (28)––only 25% of affinities in Plat-
inum are also present in BindingDB.
Platinum is the first comprehensive database of its kind
that provides experimental information related to changes
in protein–ligand affinities upon mutation and their three-
dimensional structures. Besides providing a collection of
affinity and structural data, various analyses and links to
web-based databases have been integrated into Platinum to
facilitate the detailed examination of these mutations. Plat-
inum will also be useful for developing novel in silico pre-
dictive approaches.
We have observed that predicted changes in protein sta-
bility and protein–protein affinity upon mutation show a
poor correlation with experimentally measured changes in
ligand affinity; therefore a new general method to encom-
pass these effects is required. Some properties appear to cor-
relate better with affinity change, including the distance of
the mutated residue to the binding site as well as changes in
residue properties. We are currently using structural signa-
tures togetherwith these observations to develop a universal
predictive method. The accurate prediction of the changes
in ligand affinity upon mutation may not only enhance our
understanding of ligand binding and aid in the drug devel-
opment process but also allow directed administration of
therapeutics most likely to be efficacious.
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